Your FDA/EMA Dossier Will Not Pass EAEU Validation. Ten Differences That Block Registration
An international manufacturer that has successfully registered a product in the US and Europe often enters the EAEU market with full confidence: «We have the Common Technical Document (CTD), we know ICH M4, everything is ready.» A year later, it turns out that far from everything was ready. The application is rejected at the validation stage, the GMP certificate is not accepted, and the quality specification document had to be written from scratch. Twelve to eighteen months lost, along with several million rubles.
Formally, the EAEU has adopted the ICH CTD structure and its five-module dossier. Behind this formal similarity, however, hide ten fundamental discrepancies, any one of which can halt registration entirely.
Let us break them down one by one: what exactly differs, why it matters, and what to do about it.
Three Systems, Three Approaches
The FDA, EMA, and EAEU all address the same goal: ensuring safe and effective medicines reach the market. Their approaches, however, are fundamentally different.
The FDA operates a unitary, centralized system. A single federal agency controls everything from clinical trials to post-marketing surveillance. The legal framework is the Code of Federal Regulations (21 CFR); decisions are precedent-based and procedures are flexible. The EMA uses a networked, decentralized model: the agency coordinates the work of national regulators across 27 member states, providing mutual recognition and a centralized procedure for innovative drugs. Scientific evaluation sits at the EMA level; the formal legal decision is issued by the European Commission.
The EAEU sits between these two models and currently leans closer to the decentralized approach. There is no single supranational agency: registration is conducted by the competent authorities of five member states under unified rules established by Decision of the EAEU Council No. 78 dated November 3, 2016 (as amended on November 26, 2025; hereinafter—Rules No. 78). Each member state retains sovereign authority when issuing a Marketing Authorization (MA).
This means that a layer of Soviet and post-Soviet regulatory traditions has been superimposed onto the ICH CTD format—primarily in the area of quality control. This is where the majority of practical difficulties are concentrated.
Ten Differences You Must Know Before Filing a Dossier
1. EAEU GMP Does Not Recognize Western Certificates
This is the most painful barrier, and the most frequently underestimated—precisely because it is administrative rather than scientific.
The FDA and the European Union are bound by Mutual Recognition Agreements (MRA) for GMP inspections. If a European regulator has already inspected a facility, the FDA can accept that result without dispatching its own inspectors. The arrangement works both ways.
There is no such system in the EAEU. Under Paragraph 29 of Rules No. 78, when submitting a registration application, the applicant must present a valid document confirming compliance of the manufacturing site with EAEU GMP requirements. A certificate issued by the FDA, EMA, or any other Western regulator is not automatically recognized.
Paragraph 30 of Rules No. 78 offers an alternative path. If an EAEU GMP certificate is not available, the applicant may submit a document package instead: a certificate from the competent authority of the manufacturing country, the latest inspection report from the preceding three years, quality complaint records, the Site Master File, and formal consent to an EAEU inspection. Based on these materials, the competent authority of the Reference Member State (RMS) decides whether to conduct an unscheduled inspection immediately or to include the site in the inspection plan for the first three years post-registration.
The backlog for inspections at Russia’s State Institute for Drugs and Good Practices (GILSiNP) can reach 12–18 months. The decision on whether to order an unscheduled inspection must be taken no later than 70 working days from the application submission date (Paragraph 58 of Rules No. 78).
What this means in practice. Your regulatory strategy must begin not with drafting the dossier, but with filing the EAEU GMP inspection application—ideally 1.5 to 2 years before the planned registration date.
2. The Normative Document on Quality
This is a feature unique to the EAEU that simply does not exist in the FDA or EMA frameworks.
In Western systems, quality specifications and analytical methods form an integral part of Module 3 (sections 3.2.P.5.1 and 3.2.P.5.2). These documents live inside the dossier and hold no independent legal status outside it.
In the EAEU, the Normative Document on Quality (ND) is defined separately. It is a document that «establishes the quality control requirements for a medicinal product… and is approved by the competent authority during registration» (Paragraph 19 of Rules No. 78). After registration, the ND receives its own unique number and becomes a quasi-regulatory act, binding by law.
Any deviation from the methodology described in the ND—even if permissible under ICH as a minor variation—requires a formal variation submission to update the document. The ND content is tightly regulated and frequently includes tests that Western systems perform only at batch release or have phased out entirely as redundant.
What to do. Draft the ND well in advance of finalizing Module 3. Align the list of quality parameters with the requirements of the EAEU Pharmacopoeia.
3. Legalization of Documents
The FDA and EMA rely entirely on electronic submission: standard eCTD, electronic signatures, portal-based verification. There are no notaries.
In the EAEU, Module 1 documents of foreign origin—Powers of Attorney, manufacturing licenses, Certificates of Pharmaceutical Product (CPP), corporate incorporation documents—require notarized copies with an Apostille (for Hague Convention countries) or consular legalization. The Russian translation must also be notarized.
A translation error in a single technical term can lead to rejection of the entire package at the validation stage. Obtaining an Apostille in the US or EU countries can take anywhere from two weeks to two months.
What to do. Launch the legalization and apostille workflows in parallel with drafting the dossier. Do not leave this for the final assembly stage.
4. Technical Submission Format
Formally, both the FDA/EMA space and the EAEU speak the language of electronic CTD. Technically, they are entirely different implementations.
The FDA and EMA use the ICH eCTD v3.2.2 standard, transitioning to v4.0. The foundation is an index.xml backbone file that links documents and manages their lifecycle. The market offers dozens of ready-made publishing solutions for this format.
In the EAEU, the technical requirements for electronic submission are governed by Decision of the EEC College No. 79 dated June 30, 2017 (as amended on April 19, 2022). The submission format is a zip archive containing PDFs and XML files. The structure R.017 («Information on the application for registration of a medicinal product») requires entering product attributes—composition, packaging, manufacturers—as structured data, not simple PDF attachments. In parallel, the structure R.022 («Information on the registration file or registration dossier of a medicinal product») is used. The technical schemas for R.017 and R.022 are maintained and published by the Commission itself.
Standard eCTD validators such as Lorenz or eValidator are not suitable for the EAEU without specialized regional add-on modules. Document lifecycle management, routine in the FDA system, functions differently under the EAEU schema.
What to do. Confirm that your publishing software is compatible with the EAEU XML schemas before starting dossier compilation. Do not rely on tools that worked for FDA/EMA.
5. Summary of Product Characteristics and Package Leaflet
The FDA uses Prescribing Information (USPI)—a single document for healthcare professionals. The EMA has long separated these functions: the SmPC (Summary of Product Characteristics) for professionals and the Package Leaflet (PL) for patients.
The EAEU follows the European path. Decision of the EAEU Council No. 88 (as amended on February 21, 2025, No. 18) introduces the Summary of Product Characteristics (SmPC / ОХЛП) and the Package Leaflet (PL / ЛВ). In practice, the legacy Soviet term «Instructions for Medical Use» (ИМП) continues to appear in expert queries, having historically combined both documents into one.
When submitting to multiple EAEU countries, translations into the official state languages of the relevant member states are required. Unlike the EMA’s centralized procedure—where translations are finalized after approval—the EAEU frequently requires them at the time of submission, creating a real risk of version desynchronization across markets.
6. Readability User Testing of the Package Leaflet
For the EMA, this is a long-established standard: Directive 2001/83/EC requires consultation with target patient groups (readability user testing) for the package leaflet.
In the EAEU, readability testing requirements are set out in Paragraph 7.1 and Annexes 14, 17, and 18 of Decision No. 88 (as amended on February 21, 2025, No. 18). The PL developer is required to follow the readability guidelines and assess comprehension through formal testing. The test must be conducted with at least 20 participants from the product’s target demographic; the resulting report must be included in the registration dossier.
For companies that have previously operated solely within the FDA framework, this is a completely new procedural requirement. For European companies, the challenge is different: the Russian-language version must be tested on a Russian-speaking population. Simply transferring the results of an English-text readability test is not accepted without specific scientific justification.
What to do. Allocate a separate budget and timeline for PL development and localized user testing at the early planning stage.
7. Reference Product for Bioequivalence
The rules for selecting a reference product diverge more significantly than they appear on paper.
For generics, the FDA and EMA allow use of a Reference Listed Drug (RLD) sourced from their own markets. Data can also be bridged from another ICH country, provided identicality is demonstrated.
The EAEU requires that the reference product be registered within the Union. Using a product sourced from the EU or US is permitted only if it is neither registered nor circulating anywhere in the EAEU—but even then, you must prove the identicality of manufacturing sites and quantitative composition. In practice, this is often impossible without access to the innovator’s proprietary data. The EAEU bioequivalence rules established by Decision of the EAEU Council No. 85 (as amended on May 15, 2025) are strict on this point.
What this means. Bioequivalence study data generated for the FDA or EMA generally cannot be transferred directly into an EAEU dossier. Repeat studies are a real possibility.
8. Clinical Data and Local Participation
The EMA and FDA have long applied ICH E5 flexibly, accepting foreign clinical data with adequate scientific justification.
The EAEU broadly accepts ICH E5 principles, but Paragraph 36 of Rules No. 78 sets a firm condition. Clinical trials initiated after January 1, 2016, are accepted only if at least one of them was conducted fully or partially within the territory of the Union. If this condition is not met, the competent authority may order an additional inspection of the foreign clinical centers or require a local bridging study.
For socially significant diseases—tuberculosis, HIV, hepatitis—the epidemiology and standard-of-care guidelines in the EAEU differ from Western protocols. This adds further risk that a purely Western clinical data package will not be accepted without modification.
9. Combination Products
Pre-filled syringes, auto-injectors, inhalers—anything where a drug is delivered via an integrated device—falls into a zone of heightened regulatory scrutiny in the EAEU.
The FDA treats such combinations as a single entity and processes a single application covering both components. The EMA requires either a CE-mark for the device or a formal Notified Body opinion.
In the EAEU the situation is more complex. Paragraph 187 of Rules No. 78 (as amended by Decision No. 12 dated January 22, 2025) distinguishes three scenarios. First: the device is not classified as a medical device under Union acts, and its data is included in Module 3. Second: the device is recognized as a medical device but is marketed exclusively co-packaged with the drug; separate medical device registration is not required, but technical data on the device must be included in the dossier. Third: the device is registered as an independent medical device under EAEU Council Decision No. 46 dated February 12, 2016, in which case a copy of its standalone registration certificate must accompany the drug dossier.
What to do. Determine the regulatory status of your device under EAEU classification before beginning work on the dossier and choose your strategy accordingly.
10. Pharmacovigilance and Local Infrastructure
The EMA requires an EU-QPPV residing in the EU and a centralized Pharmacovigilance System Master File (PSMF).
The EAEU GVP rules, established by Decision of the EAEU Council No. 79 dated November 3, 2016, require a Qualified Person for Pharmacovigilance (QPPV) residing and operating within an EAEU member state. When submitting via the Mutual Recognition Procedure to multiple countries, local pharmacovigilance contact persons are also required in each Concerned Member State. The Risk Management Plan (RMP) must contain country-specific local specifications for each state of submission.
The global PSMF requires localization: in Russia, the localized PSMF is a formally recognized document. Under Paragraph 150 of Rules No. 78, the regulator may request a copy of the PSMF at any time, and the Marketing Authorization Holder is required to deliver it within 10 working days of receiving the request.
What to do. Build or outsource a network of QPPVs and local pharmacovigilance contact persons across the targeted EAEU member states well before registration—not after.
Summary Comparison Table
| Feature | FDA / EMA | EAEU | Risk |
|---|---|---|---|
| GMP Certification | Mutual Recognition Agreements (MRA) | Independent EAEU GMP certificate required | 12–18 month delays |
| Normative Document | Part of Module 3 | Standalone legally binding quality act | Errors = rejection |
| Document Legalization | Electronic submission | Apostille + notarized Russian translation | Logistical delays |
| Technical Format | ICH eCTD v3.2.2 / v4.0 | Custom XML schemas R.017 / R.022 | Software incompatibility |
| SmPC / PL | USPI or SmPC + PL | SmPC + PL with EAEU-language translations | Version desynchronization |
| Readability Testing | EMA standard | Mandatory, 20 participants, Russian version | New procedure for FDA-only companies |
| Reference Product | Sourced from any ICH-region market | Must be registered within the EAEU | Repeat bioequivalence studies |
| Clinical Data | ICH E5, bridging accepted | EAEU center participation required (post-2016) | Additional clinical trials |
| Combination Products | Single unified application | Depends on device regulatory status | Dual registration risk |
| Pharmacovigilance | EU-QPPV + centralized PSMF | QPPV per EAEU state + localized PSMF | Infrastructure costs |
What to Do
The sequence of actions here matters just as much as their content. Several workstreams must run in parallel, and one must be started before all others.
Start with the GMP inspection. Before beginning any module of the dossier, check the EAEU GMP status of every manufacturing site involved. If no certificate exists: submit documents under Paragraph 30 of Rules No. 78 and initiate the inspection request without delay. This takes 12–18 months for scheduling and completion alone.
Conduct a Module 3 GAP audit. Compare your existing API and finished product specifications against the current EAEU Pharmacopoeia. Identify which additional tests are needed for the Normative Document. Draft the ND project in parallel with finalizing the module—not after.
Launch document legalization. Draw up a complete list of Module 1 documents requiring an Apostille and notarized translation. Start the process immediately: it takes months and should not block the final submission assembly.
Review your clinical package. Confirm whether your clinical data meets the conditions of Paragraph 36 of Rules No. 78. If pivotal trials were initiated after 2016 without any EAEU sites, discuss with the Reference Member State in advance the scope of any additional data required or whether a clinical site inspection could serve as an alternative.
Build your pharmacovigilance infrastructure. Appoint or contract QPPVs in each EAEU state where registration is planned. Localize the global RMP for each country and ensure the localized PSMF can be produced within the 10-working-day notice window.
From the moment preparation begins, a full registration in the Reference Member State—accounting for the EAEU GMP inspection—will realistically take 2 to 3 years. In the Concerned Member States the procedure takes a further 40 to 60 working days following approval in the RMS (Paragraphs 68–69 of Rules No. 78). Time spent responding to expert queries (up to 90 working days) is not counted within these official timelines.
An existing FDA or EMA dossier is a solid starting point: clinical data is generally accepted and the CTD structure is familiar to local experts. Treating it as a ready-to-file EAEU dossier, however, means underestimating the scope of adaptation required. Registration is most often stalled at the administrative and procedural level—GMP, the Normative Document, legalization, XML architecture. Companies that enter the EAEU with a clear picture of these challenges from the outset save time and do not lose market access.
Regulatory Framework:
1. Decision of the EAEU Council No. 46 dated February 12, 2016 «On the Rules for Registration and Expert Evaluation of Medical Devices» (as amended on March 30, 2023)
2. Decision of the EAEU Council No. 78 dated November 3, 2016 «On the Rules for Registration and Expert Evaluation of Medicinal Products for Human Use» (as amended on November 26, 2025)
3. Decision of the EAEU Council No. 77 dated November 3, 2016 «On the Rules of Good Manufacturing Practice of the Eurasian Economic Union» (as amended on November 19, 2025)
4. Decision of the EAEU Council No. 79 dated November 3, 2016 «On the Rules of Good Pharmacovigilance Practice» (as amended on March 23, 2023)
5. Decision of the EAEU Council No. 85 dated November 3, 2016 «On the Rules for Conducting Bioequivalence Studies of Medicinal Products» (as amended on May 15, 2025)
6. Decision of the EAEU Council No. 88 dated November 3, 2016 «On the Requirements for the Package Leaflet and Summary of Product Characteristics of Medicinal Products» (as amended on February 21, 2025, No. 18)
7. Decision of the EEC College No. 79 dated June 30, 2017 «On the Requirements for the Electronic Form of Applications and Registration Dossier Documents» (as amended on April 19, 2022)